March 26, 2018 / 1:40 PM / 6 months ago

BRIEF-Biohaven Pharma Says Safety Profile Thus Far Favours Rimegepant, In Comparison With Allergan's Ubrogepant

March 26 (Reuters) - Allergan Plc:

* BIOHAVEN PHARMACEUTICAL SAYS IN TERMS OF COMPARISON OF RIMEGEPANT WITH ALLERGAN'S UBROGEPANT, THE SAFETY PROFILE THUS FAR FAVOURS RIMEGEPANT - CONF CALL

* BIOHAVEN PHARMACEUTICAL SAYS "WE'RE GONNA HAVE A LOT OF OPTIONALITY WITH REGARD TO HOW WE COMMERCIALIZE" RIMEGEPANT - CONF CALL Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below